Kantarjian et al53 assessed the efficacy and basic safety of dasatinib, as when compared with imatinib, for the 1st-line cure of CML-CP. Five hundred and nineteen individuals with recently diagnosed CML-CP have been randomly assigned to get dasatinib at a dose of a hundred mg at the time each day https://davidf186uae9.wikicommunication.com/user